Catalent

Corporate brand

Catalent is a global contract development and manufacturing organization serving pharmaceutical, biotech, and consumer health companies.

Last updated September 25, 2026

AI crawler reads

2requests

1companies

Anthropic2

Profile: 2
Controversies: 0
JSON · MD: 0

First read: Nov 4, 2026
Latest read: Nov 4, 2026

From this site's server log

Overview

Catalent is a global contract development and manufacturing organization (CDMO) that works with pharmaceutical, biotechnology, and consumer health companies. Its stated mission is to develop, manufacture, and supply products intended to help people live better and healthier lives. The company describes its work as supporting customers from early-stage development through commercial manufacturing and delivery, with a focus on patients and consumers. Its service areas include small molecules, biologics, cell and gene therapies, and clinical supply. Catalent presents its offering as an integrated network combining technical expertise, technologies, and manufacturing capabilities to help customers develop and deliver medicines, therapies, and self-care products. Its stated customers include innovators in pharma and biotech as well as consumer health companies. The company says its history began with R.P. Scherer in 1933, associated with a patented rotary-die softgel process, and that Catalent was formed under that name in 2007. It describes subsequent growth through acquisitions and investments, building capabilities across oral products, biologics, and advanced modalities, including cell and gene therapy. The company also says it supplied vaccine and therapeutic doses during the COVID-19 pandemic and expanded its self-care capabilities. Catalent presents itself as a partner to customers rather than as a consumer-facing medicine brand. Its stated priorities include patient-first work, service, quality, reliability, responsible business practices, and collaboration. The company says its network serves global markets. The supplied sources do not identify its current owner, headquarters, or listed status.

History

Catalent traces part of its history to R.P. Scherer, whose rotary-die softgel process is described by the company as a patented medicine-delivery innovation dating to 1933. Catalent says that this process was honored by the Smithsonian in 1955. The company also identifies later technologies—including Zydis fast-dissolve tablets, Liqui-Gels, and GPEx cell-line development—as part of the innovation history that helped shape its capabilities. Catalent was formed under its current name in 2007. The company describes its subsequent development as a combination of acquisitions and investments intended to build an end-to-end service ecosystem across oral products, biologics, and advanced modalities, including cell and gene therapy. Its current service description covers small molecules, biologics, cell and gene therapies, and clinical supply, with support spanning early-stage development through commercial manufacturing. The company says that during the COVID-19 pandemic it delivered billions of vaccine and therapeutic doses worldwide while also expanding its self-care capabilities. Today, Catalent describes itself as a global CDMO serving pharmaceutical, biotech, and consumer health companies. It frames its mission around developing, manufacturing, and supplying products that help people live better and healthier lives, and emphasizes patient-first priorities, service, quality, partnership, and responsible operations. The supplied evidence does not establish a more detailed ownership, headquarters, or public-listing history.

2007
Catalent is formed
1955
Softgel process recognized by the Smithsonian
1933
R.P. Scherer history begins
Expansion into an end-to-end services ecosystem
COVID-19 pandemic response

Products and positioning

A global, end-to-end CDMO partner for pharma, biotech, and consumer health companies, emphasizing integrated development and manufacturing, technical expertise, quality, reliability, and patient-focused outcomes.

Integrated CDMO services
Development, manufacturing, and supply services for pharmaceutical, biotech, and consumer health customers.
Small-molecule services
A stated area of Catalent's integrated pharma CDMO offering.
Biologics
A stated area of development and manufacturing capability.
Cell and gene therapies
An advanced-modality service area named by the company.
Clinical supply
A service area in Catalent's integrated CDMO portfolio.
Zydis fast-dissolve tablets, Liqui-Gels, and GPEx cell-line development
Technologies cited by Catalent as part of its history of innovation.

Recent events

2021.07.26
Reported2021.07.26
Catalent launches OptiDose Design Solution[6]Catalent推出OptiDose Design Solutionprweb.com
Catalent announced the launch of its OptiDose Design Solution, a dose-form design solution intended to combine data-driven scientific tools with Catalent's development expertise. It is available throughout Catalent's global oral dose network.
2021.07.22
Reported2021.07.22
Catalent launches GPEx Lightning cell line development technology[7]Catalent推出GPEx Lightning细胞系开发技术prweb.com
Catalent announced the launch of GPEx Lightning, a next-generation cell line development technology that it says can shorten drug-substance development by up to three months compared with previous timelines.
2021.06.28
Reported2021.06.28
Catalent receives RoSPA Gold Health and Safety Award[8]Catalent获得RoSPA健康与安全金奖prweb.com
Catalent announced that it had received the RoSPA Gold Health and Safety Award for its work to provide a safe, healthy and inclusive working environment. The award presentation was scheduled for September 9, 2021.
2021.05.06
Reported2021.05.06
Catalent acquires HCTS and its Gosselies facility[9]Catalent收购HCTS及其戈斯利设施prweb.com
Catalent acquired Promethera's cell therapy manufacturing subsidiary, Hepatic Cell Therapy Support SA (HCTS), including its facility in Gosselies, Belgium.
2021.03.17
Reported2021.03.17
Catalent and Janssen expand vaccine manufacturing partnership[10]Catalent与Janssen扩大疫苗生产合作prweb.com
Catalent announced an expanded partnership with Janssen to increase manufacturing capacity for Janssen's COVID-19 vaccine at Catalent's Anagni, Italy facility, including vial-filling, inspection, labeling, and packaging services. An additional high-speed vial-filling line was expected to be operational in the fourth quarter of 2021.
2021.02.11
Reported2021.02.11
Acorda and Catalent enter global supply agreement for INBRIJA[11]Acorda与Catalent就INBRIJA签订全球供应协议biospace.com
In connection with the sale of Acorda's manufacturing operations, Acorda and Catalent entered a long-term global supply agreement under which Catalent will manufacture and package INBRIJA for Acorda.
2021.02.11
Reported2021.02.11
Acorda completes sale of manufacturing operations to Catalent[11]Acorda与Catalent就INBRIJA签订全球供应协议biospace.com
Acorda Therapeutics announced that it had completed the sale of its manufacturing operations in Chelsea, Massachusetts, to Catalent for $80 million in cash.
2021.01.13
Reported2021.01.13
Acorda announces agreement to sell Chelsea manufacturing operations[12]Acorda宣布出售Chelsea制造业务的协议biospace.com
Acorda announced a definitive agreement to sell its INBRIJA manufacturing operations in Chelsea, Massachusetts, to Catalent for $80 million in cash. Completion remained subject to customary closing conditions and was expected in the first quarter of 2021.
2021.01.13
Reported2021.01.13
Acorda and Catalent enter long-term INBRIJA supply agreement[12]Acorda宣布出售Chelsea制造业务的协议biospace.com
Acorda and Catalent entered into a long-term global supply agreement under which Catalent will manufacture and package INBRIJA for Acorda.
2020.10.19
Reported2020.10.19
Catalent announces OptiGel DR technology launch[13]Catalent宣布推出OptiGel DR技术prweb.com
Catalent announced the launch of OptiGel DR technology for formulating and manufacturing delayed- or enteric-release softgels. The technology combines pectin with gelatin in the softgel capsule, eliminating the need for a separate capsule-coating step.

Sources29 sources

Cite this profile: Cite the canonical profile. /brand-wiki/catalent · Editorial policy · How profiles are compiled